Current Report Filing (8-k)
May 15 2020 - 8:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): May 15, 2020
Edesa Biotech,
Inc.
(Exact Name of
Registrant as Specified in its Charter)
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer Identification
No.)
|
|
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6
|
(Address of Principal Executive
Offices)
|
(289) 800-9600
Registrant’s telephone
number, including area code
N/A
(Former name or former
address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions (see
General Instruction A.2. below):
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to
Section 12(b) of the Act:
Title of each
class
|
|
Trading
Symbol(s)
|
|
Name of exchange
on which registered
|
Common Shares
|
|
EDSA
|
|
The Nasdaq Stock Market
LLC
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02 Results of Operations and
Financial Condition.
On May 15, 2020, Edesa Biotech,
Inc. (the “company”) issued a press release announcing
its financial results for the three-month and six-month periods
ended March 31, 2020 (the “Earnings Release”). The full
text of the Earnings Release is attached hereto as Exhibit 99.1.
The information furnished herein and therein shall not be deemed
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that Section, or incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such a filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press release issued by Edesa
Biotech, Inc. dated May 15, 2020.
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Edesa Biotech,
Inc.
|
|
|
|
Date: May 15,
2020
|
By:
|
/s/
Kathi Niffenegger
|
|
Name:
|
Kathi
Niffenegger
|
|
Title:
|
Chief Financial
Officer
|
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Edesa Biotech (NASDAQ:EDSA)
Historical Stock Chart
From Sep 2023 to Sep 2024